^
Association details:
| Biomarker: | KRAS G12D + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2380 / 9 - The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model
Published date:
03/09/2022
Excerpt:
We started our in vivo experiments comparing the response of the tumors characterized by the mutation in KRASG12D or the co-mutation KRASG12D/LKB1mut….Our in vivo preliminary studies confirm our hypothesis that the addition of the caloric restriction and metformin is able to improve the antitumor activity of the cisplatin without increasing the treatment toxicity in tumors characterized by the co-mutations of KRASG12D/LKB1mut.
Secondary therapy:
metformin
